Business Wire

Brightcove Powers Japan’s Newest Streaming Service, J:COM’s “Animal Watch”

7.6.2024 07:00:00 EEST | Business Wire | Press release

Share

Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, announced today that it is welcoming JCOM Co., Ltd. (J:COM), Japan’s largest cable TV company, as a new customer. As the streaming technology partner for J:COM, Brightcove is powering the media company’s newest streaming service, Ikimono Watch (“Animal Watch”), which plans to broadcast content from across Japan’s zoos and aquariums.

“J:COM is Japan's biggest and most respected cable company. We’re honored to collaborate closely with them on this new venture to provide a high-quality and engaging streaming experience for viewers across Japan,” said Chiyo Yanagita, Country Manager, Brightcove Japan. “J:COM’s decision to choose Brightcove is a testament to our platform’s reliability, security, and ability to scale and grow with the service.”

The new streaming app, Ikimono Watch, works with J:COM set-top boxes and was built with Brightcove’s Android software development kit (SDK). Brightcove’s Video Cloud securely houses all of the video content sourced from zoos and aquariums across Japan, and the Video Cloud API is integrating with the app’s content management system (CMS) to retrieve content and ensure a smooth, efficient viewing experience.

“By choosing Brightcove's platform, we were able to ensure a smooth launch for our ‘Ikimono Watch’ project. The company’s experience in video distribution and handling various types of content has contributed greatly to the efficient and successful introduction of our new streaming service. Video Cloud is indispensable to the strategy of Ikimono Watch, and we look forward to its future growth,” ​​shared Mr. Masaki Uchiyama, J:COM General Manager, Next Gen. Platform Development Department, Service Planning Division.

J:COM joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including Acun Medya, AMC Networks, BBC Studios, Canela Media, LIXIL Corporation, MotoAmerica, NHL, One31, REELZ, SBT TV, SHISEIDO, SKY Mexico, The Academy of Motion Pictures and Sciences, The National Academy of Television Arts & Sciences, Wacoal and Yahoo.

For more information, visit Brightcove.com.

About JCOM Co., Ltd.
Established in 1995, JCOM Co., Ltd.(J:COM) is Japan's largest multiple system and multiple channel operator. In system operation, J:COM provides cable television, high speed internet access, telephony, mobile, electric power service, and services based on IoT devices to customers through 11 consolidated subsidiaries at the local level serving 5.68million subscribing households in Sapporo, Sendai, Kanto, Kansai, and Kyushu-Yamaguchi regions. The number of serviceable households or “homes passed” in J:COM franchise areas is 22.42 million. In channel operation, J:COM invests in and operates 14 thematic channels which are provided to CATV, satellite and telecom operators.

※ The above subsidiaries and household figures are as of Mar 31, 2024.

About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Brightcove
Joseph J. Nuñez
Director of Global Communications and Public Relations
jnunez@brightcove.com

JCOM Co., Ltd.
Public Relations
TEL:080-5965-0001(Uchikawa)
E-Mail:uchikawam@jupiter.jcom.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye